Claudin18.2 in G/GEJ: Module

CME

Claudin18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 25, 2023

Expiration: April 24, 2024

Manish Shah
Manish Shah, MD

Activity

Progress
1
Course Completed

References

  1. World Health Organization. GLOBOCAN 2020: stomach cancer fact sheet. gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf. Accessed April 10, 2023.
  2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: gastric cancer. v.2.2022. nccn.org. Accessed April 10, 2023.
  3. Baek JH, Park DJ, Kim GY, et al. Clinical implications of claudin18.2 expression in patients with gastric cancer. Anticancer Res. 2019;39:6973-6979.
  4. Mao L, Yi W, Lin XA, et al. Prevalence of claudin18.2 and PD-L1 expression in Chinese gastric/gastroesophageal junction adenocarcinoma. Presented at: Society for Immunotherapy of Cancer 37th Annual Meeting; November 8-12, 2022. Abstract 105.
  5. Cao W, Xing H, Li Y, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10:38.
  6. Sahin U, Tureci O, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609-619.
  7. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023.
  8. Xu RH, Shitara K, Ajani JA et al. Zolbetuximab + CAPOX in 1L Claudin-18.2+ (CLDN18.2+)/HER2- locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ): primary phase 3 results from GLOW. Presented at: American Society of Clinical Adenocarcinoma Oncology Plenary Series; March 22, 2023. Abstract 405736.
  9. Shen L, Gong J, Li N, et al. Updated report of a phase I study of TST001, a humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer. Presented at: European Society for Medical Oncology Congress; September 9-13, 2022. Abstract 3520.
  10. Zhang M, Gong J, Wang J, et al. A phase I/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 18-21, 2023. Abstract 397.
  11. Suurs FV, Lub-de-Hooge MN, de Vries E, et al. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019;201:103-119.
  12. Wang YK, Gong J, Sun Y, et al. Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 18-21, 2023. Abstract 382.
  13. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327-344.
  14. Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadek R, et al. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11:3-23.
  15. Rinnerthaler G, Gampenrieder SP, Greil R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int J Mol Sci. 2019;20:1115.
  16. Shitara K, Baba E, Fujitani K, et al. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer. 2021;24:780-789.
  17. Xu RH. A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 18-21, 2023. Abstract 352.
  18. Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724-740.
  19. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45.
  20. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.
  21. Dwivedi A, Karulkar A, Ghosh S, et al. Lymphocytes in cellular therapy: functional regulation of CAR T cells. Front Immunol. 2018;9:3180.
  22. Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189-1198.
  23. Botta GP, Becerra CR, Jin Z, et al. Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma. Presented at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 2538.